Full Breakdown
Trump Signs Executive Order to Reclassify Marijuana
12/20/2025, 11:31:23 AM
Major Shift in Federal Drug Policy
On December 18, 2025, President Donald Trump signed an executive order to reclassify marijuana from a Schedule I drug to a Schedule III substance under the Controlled Substances Act. This significant change acknowledges the potential medical uses of cannabis, which has long been classified alongside heroin and LSD as having no accepted medical use and a high potential for abuse. The reclassification allows marijuana to be recognized as having legitimate medical applications, similar to medications like Tylenol with codeine and ketamine.
The executive order aims to facilitate medical research on cannabis, which has been hindered by its previous classification. Trump emphasized the need for this change, stating, “We have people begging for me to do this. People who are in great pain.” The order directs Attorney General Pam Bondi to expedite the rescheduling process, which has been under review for over a year.
Implications for Medical Research and Cannabis Industry
The reclassification is expected to ease regulatory barriers for researchers, allowing for more comprehensive studies on the medical benefits and risks associated with marijuana. Currently, many researchers avoid studying Schedule I substances due to the extensive bureaucratic hurdles involved. By moving cannabis to Schedule III, the executive order is anticipated to open the door for clinical trials and evidence-based standards of care.
Additionally, the change could have significant financial implications for the cannabis industry. Under the previous Schedule I classification, cannabis businesses faced severe tax burdens due to IRS Code Section 280E, which prohibits tax deductions for expenses related to trafficking in controlled substances. The new classification would allow these businesses to deduct standard expenses, potentially alleviating financial pressures and encouraging growth within the industry.
Official Statements and Responses
The Trump administration has framed this executive order as a response to the needs of patients suffering from chronic conditions. A senior administration official stated, “The President is very focused on the potential medical benefits and has directed a commonsense approach to improve medical marijuana and CBD research.”
However, the order does not legalize marijuana for recreational use, and Trump reiterated that it does not sanction its use as a recreational drug. “It doesn’t legalize marijuana in any way, shape, or form,” he clarified.
Criticism and Opposition
Despite the potential benefits, the executive order has faced criticism from various quarters. A group of 22 Republican senators urged Trump to maintain marijuana's Schedule I status, arguing that reclassification could send the wrong message about the drug's safety, particularly to youth. They expressed concerns that facilitating the growth of the marijuana industry could undermine public health and safety.
Critics, including representatives from the Smart Approaches to Marijuana organization, labeled the move a “public health disaster,” arguing that it would primarily benefit large cannabis corporations rather than addressing the needs of patients.
What's Next?
The executive order marks a pivotal moment in U.S. drug policy, potentially paving the way for further reforms. While the immediate effects of the reclassification will take time to materialize, it signals a shift towards recognizing the medical value of cannabis. The administration plans to work with Congress to enhance access to CBD products and develop a regulatory framework for hemp-derived cannabinoids.
As the federal government begins to acknowledge the medical applications of marijuana, the landscape of cannabis research and industry regulation is poised for significant transformation. However, the ongoing debate about the implications of this change continues, with advocates and opponents alike closely monitoring its impact on public health and safety.
